摘要
目的研究肾小管1号方治疗肾小管间质功能受损的CKD1~3期患者的临床疗效。方法将60例肾小管间质功能损伤的CKD1~3期患者随机分为对照组和治疗组,对照组予缬沙坦胶囊160 mg qd+百令胶囊1.5 g tid口服,治疗组加用肾小管1号煎服,总疗程12周,采集患者治疗前后血、尿标本,观察血肌酐、尿RBP酶(视黄醇结合蛋白,Retinol-Binding Protein,RBP)、尿NAG酶(N-乙酰-β氨基葡萄糖苷酶,N-Acetyl-β-Glucosaminidase,NAG)、尿β2-微球蛋白(β2-MG)、24 h尿蛋白定量的变化。结果两组治疗12周后24 h尿蛋白定量、尿RBP酶、尿NAG酶、尿β2-微球蛋白指标均较治疗前改善,治疗组比对照组各指标改善情况更显著(P<0.05)。结论肾小管1号方治疗肾小管间质功能损伤的慢性肾脏病1~3期患者疗效显著,能够降低肾小管的标志性蛋白/酶,减轻肾小管间质功能损伤。
Objective To study the clinical efficacy of renal tubule 1 in the treatment of CKD1-3 patients with im- paired renal tubular interstitium function. Methods 60 CKD1-3 patients with renal tubular interstitium function injury were randomly divided into control group and treatment group. The control group received valsartan capsule 160 mg qd＋ Bailing capsule 1.5 g tid orally. The treatment group was also given renal tubule 1 decoction. The total course of treatment was 12 weeks. The blood and urine specimens of patients before and after treatment were collected. The changes of serum creatinine, urinary RBP enzyme （Retinol-Binding Protein, RBP）, urinary NAG enzyme （N-Acetyl-6-Glu cosaminidase, NAG）, urinary β2-microglobulin（β2-MG）, 24-hour urinary protein quantification were observed. Results The 24-hour urinary protein quantitation, urinary RBP enzyme, urinary NAG enzyme, and urine β2-microglobulin were improved after the 12 months of treatment in the two groups compared with those before treatment. The improvement t in the treatment group was more significant than that in the control group （P〈0.05）. Conclusion Renal tubule 1 is effec tire in treating 1-3 stages of chronic kidney disease with renal tubulointerstitial injury, which can reduce the tubular iconic protein/enzyme and reduce renal tubulointerstitial injury.
作者
赵俊
徐业
黄科
王力勇
娄成利
徐秀琴
王向晶
ZHAO Jun;XU Ye;HUANG Ke;WANG Liyong;LOU Chengli;XU Xiuqin;WANG Xiangjing(Department of Nephrology,Jiaxing Hospital of Traditional Chinese Medicine,Jiaxing 314001,China)
出处
《中国现代医生》
2018年第18期111-114,共4页
China Modern Doctor
基金
浙江省中医药科技计划项目(2016ZB126)
